Drug firm Laurus Labs Friday said audit of its unit 4 at Visakhapatnam in Andhra Pradesh by the US health regulator has been completed without any observations.
"The inspection of the unit 4 was carried out from July 8 - 12, 2019," Laurus Labs said in a filing to BSE.
The maiden United States Food and Drug Administration (USFDA) audit for the unit was successfully completed without any observations and no Form 483 was issued, it added.
As per the USFDA, Form 483 notifies the company's management of objectionable conditions.
Shares of Laurus Labs were trading at Rs 354.05 per scrip on BSE, up 2.34 per cent from the previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
